{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:04:09Z","timestamp":1791083049846,"version":"4.1.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40266-018-0629-0","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T01:07:25Z","timestamp":1546996045000},"page":"189-202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"36","author":[{"given":"Mark Dominic","family":"Latt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfat","family":"Zekry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor S. C.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"issue":"1","key":"629_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0895-4356(01)00425-5","volume":"55","author":"A Elbaz","year":"2002","unstructured":"Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Risk tables for parkinsonism and Parkinson\u2019s disease. J Clin Epidemiol. 2002;55(1):25\u201331.","journal-title":"J Clin Epidemiol."},{"issue":"5","key":"629_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1212\/01.wnl.0000341769.50075.bb","volume":"72","author":"JA Driver","year":"2009","unstructured":"Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72(5):432\u20138. \n https:\/\/doi.org\/10.1212\/01.wnl.0000341769.50075.bb\n \n .","journal-title":"Neurology."},{"issue":"4","key":"629_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archneur.60.4.529","volume":"60","author":"NJ Diederich","year":"2003","unstructured":"Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003;60(4):529\u201333.","journal-title":"Arch Neurol."},{"key":"629_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jns.2016.12.046","volume":"373","author":"D Santos Garcia","year":"2017","unstructured":"Santos Garcia D, Suarez Castro E, Exposito I, de Deus T, Tunas C, Aneiros A, et al. Comorbid conditions associated with Parkinson\u2019s disease: a longitudinal and comparative study with Alzheimer disease and control subjects. J Neurol Sci. 2017;373:210\u20135. \n https:\/\/doi.org\/10.1016\/j.jns.2016.12.046\n \n .","journal-title":"J Neurol Sci."},{"key":"629_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.parkreldis.2016.11.005","volume":"35","author":"HA Beydoun","year":"2017","unstructured":"Beydoun HA, Beydoun MA, Mishra NK, Rostant OS, Zonderman AB, Eid SM. Comorbid Parkinson\u2019s disease, falls and fractures in the 2010 National Emergency Department sample. Parkinsonism Relat Disord. 2017;35:30\u20135. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.005\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"5","key":"629_CR6","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/j.1532-5415.2007.01156.x","volume":"55","author":"SK Inouye","year":"2007","unstructured":"Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780\u201391. \n https:\/\/doi.org\/10.1111\/j.1532-5415.2007.01156.x\n \n .","journal-title":"J Am Geriatr Soc."},{"issue":"11","key":"629_CR7","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s004150170047","volume":"248","author":"BR Bloem","year":"2001","unstructured":"Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson\u2019s disease. J Neurol. 2001;248(11):950\u20138.","journal-title":"J Neurol."},{"issue":"7","key":"629_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1017\/S1092852900013560","volume":"11","author":"LL Borek","year":"2006","unstructured":"Borek LL, Amick MM, Friedman JH. Non-motor aspects of Parkinson\u2019s disease. CNS Spectr. 2006;11(7):541\u201354.","journal-title":"CNS Spectr"},{"issue":"6","key":"629_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837\u201344. \n https:\/\/doi.org\/10.1002\/mds.21956\n \n .","journal-title":"Mov Disord."},{"issue":"2","key":"629_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson\u2019s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190\u20139.","journal-title":"Mov Disord"},{"issue":"6","key":"629_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.870130605","volume":"13","author":"A Schrag","year":"1998","unstructured":"Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson\u2019s disease revisited\u2014clinical features, natural history, and mortality. Mov Disord. 1998;13(6):885\u201394. \n https:\/\/doi.org\/10.1002\/mds.870130605\n \n .","journal-title":"Mov Disord."},{"issue":"11","key":"629_CR12","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/mds.10527","volume":"18","author":"A Schrag","year":"2003","unstructured":"Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Young- versus older-onset Parkinson\u2019s disease: impact of disease and psychosocial consequences. Mov Disord. 2003;18(11):1250\u20136.","journal-title":"Mov Disord."},{"issue":"8","key":"629_CR13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.parkreldis.2014.04.013","volume":"20","author":"R Caslake","year":"2014","unstructured":"Caslake R, Taylor K, Scott N, Harris C, Gordon J, Wilde K, et al. Age-, and gender-specific incidence of vascular parkinsonism, progressive supranuclear palsy, and parkinsonian-type multiple system atrophy in North East Scotland: the PINE study. Parkinsonism Relat Disord. 2014;20(8):834\u20139. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2014.04.013\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"10","key":"629_CR14","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.4088\/JCP.15m09863","volume":"76","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Antipsychotic treatment of adults in the United States. J Clin Psychiatry. 2015;76(10):1346\u201353. \n https:\/\/doi.org\/10.4088\/JCP.15m09863\n \n .","journal-title":"J Clin Psychiatry."},{"key":"629_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/CIA.S13109","volume":"6","author":"P Glare","year":"2011","unstructured":"Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243\u201359. \n https:\/\/doi.org\/10.2147\/CIA.S13109\n \n .","journal-title":"Clin Interv Aging."},{"issue":"3","key":"629_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mds.1099","volume":"16","author":"LM Shulman","year":"2001","unstructured":"Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson\u2019s disease. Mov Disord. 2001;16(3):507\u201310.","journal-title":"Mov Disord."},{"issue":"3","key":"629_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","volume":"69","author":"A Schrag","year":"2000","unstructured":"Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson\u2019s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308\u201312.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"Suppl 1","key":"629_CR18","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","volume":"22","author":"A Sauerbier","year":"2016","unstructured":"Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson\u2019s disease. Parkinsonism Relat Disord. 2016;22(Suppl 1):S41\u20136. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.027\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"12","key":"629_CR19","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1212\/WNL.38.12.1841","volume":"38","author":"CG Goetz","year":"1988","unstructured":"Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson\u2019s disease. Neurology. 1988;38(12):1841\u20134.","journal-title":"Neurology."},{"issue":"9","key":"629_CR20","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/archneur.64.9.1242","volume":"64","author":"G Levy","year":"2007","unstructured":"Levy G. The relationship of Parkinson disease with aging. Arch Neurol. 2007;64(9):1242\u20136. \n https:\/\/doi.org\/10.1001\/archneur.64.9.1242\n \n .","journal-title":"Arch Neurol."},{"issue":"11","key":"629_CR21","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","volume":"13","author":"M Horstink","year":"2006","unstructured":"Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al. Review of the therapeutic management of Parkinson\u2019s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson\u2019s disease. Eur J Neurol. 2006;13(11):1170\u201385. \n https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01547.x\n \n .","journal-title":"Eur J Neurol."},{"issue":"9949","key":"629_CR22","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"R Gray","year":"2014","unstructured":"PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial [erratum appears in Lancet. 2014 Sep 27;384(9949):1186]. Lancet. 2014;384(9949):1196\u2013205. \n https:\/\/doi.org\/10.1016\/S0140-6736(14)60683-8\n \n .","journal-title":"Lancet."},{"issue":"9","key":"629_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2165\/00002512-200522090-00002","volume":"22","author":"A Lees","year":"2005","unstructured":"Lees A. Alternatives to levodopa in the initial treatment of early Parkinson\u2019s disease. Drugs Aging. 2005;22(9):731\u201340.","journal-title":"Drugs Aging."},{"issue":"8","key":"629_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2165\/00002512-200724080-00004","volume":"24","author":"JJ Chen","year":"2007","unstructured":"Chen JJ, Fernandez HH. Community and long-term care management of Parkinson\u2019s disease in the elderly: focus on monoamine oxidase type B inhibitors. Drugs Aging. 2007;24(8):663\u201380.","journal-title":"Drugs Aging."},{"issue":"11","key":"629_CR25","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1001\/archneur.1997.00550230060018","volume":"54","author":"SL Mitchell","year":"1997","unstructured":"Mitchell SL, Sullivan EA, Lipsitz LA. Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol. 1997;54(11):1393\u20138.","journal-title":"Arch Neurol."},{"issue":"1","key":"629_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.parkreldis.2012.06.009","volume":"19","author":"W Oertel","year":"2013","unstructured":"Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B. Treatment of patients with early and advanced Parkinson\u2019s disease with rotigotine transdermal system: age-relationship to safety and tolerability. Parkinsonism Relat Disord. 2013;19(1):37\u201342. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2012.06.009\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"5692","key":"629_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/277093a0","volume":"277","author":"JW Kebabian","year":"1979","unstructured":"Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature. 1979;277(5692):93\u20136.","journal-title":"Nature."},{"issue":"4 Supplement (1","key":"629_CR28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.58.suppl_1.S1","volume":"58","author":"P Jenner","year":"2002","unstructured":"Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson\u2019s disease. Neurology. 2002;58(4 Supplement (1)):S1\u20138.","journal-title":"Neurology."},{"issue":"4","key":"629_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/syn.21805","volume":"69","author":"P Seeman","year":"2015","unstructured":"Seeman P. Parkinson\u2019s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69(4):183\u20139. \n https:\/\/doi.org\/10.1002\/syn.21805\n \n .","journal-title":"Synapse."},{"issue":"8","key":"629_CR30","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, et al. Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840\u20134. \n https:\/\/doi.org\/10.1136\/jnnp-2013-306787\n \n .","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"4","key":"629_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/s0025-6196(11)60538-7","volume":"84","author":"JM Bostwick","year":"2009","unstructured":"Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc. 2009;84(4):310\u20136. \n https:\/\/doi.org\/10.1016\/s0025-6196(11)60538-7\n \n .","journal-title":"Mayo Clin Proc."},{"issue":"3","key":"629_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2169\/internalmedicine.52.8333","volume":"52","author":"H Utsumi","year":"2013","unstructured":"Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, et al. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson\u2019s disease. Intern Med. 2013;52(3):325\u201332.","journal-title":"Intern Med."},{"issue":"2","key":"629_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1124\/jpet.102.039867","volume":"303","author":"MJ Millan","year":"2002","unstructured":"Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791\u2013804.","journal-title":"J Pharmacol Exp Ther."},{"key":"629_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.parkreldis.2016.04.023","volume":"27","author":"RW Borgemeester","year":"2016","unstructured":"Borgemeester RW, Lees AJ, van Laar T. Parkinson\u2019s disease, visual hallucinations and apomorphine: a review of the available evidence. Parkinsonism Relat Disord. 2016;27:35\u201340. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.023\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"2","key":"629_CR35","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1124\/jpet.102.039875","volume":"303","author":"A Newman-Tancredi","year":"2002","unstructured":"Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)\/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002;303(2):805\u201314.","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"629_CR36","first-page":"37","volume":"89","author":"JA Borovac","year":"2016","unstructured":"Borovac JA. Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: a mini-review of clinical pharmacology. Yale J Biol Med. 2016;89(1):37\u201347.","journal-title":"Yale J Biol Med."},{"issue":"2","key":"629_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.arbres.2008.01.003","volume":"45","author":"M Haro-Estarriol","year":"2009","unstructured":"Haro-Estarriol M, Sabater-Talaverano G, Rodriguez-Jerez F, Obrador-Lagares A, Genis-Batlle D, Sendra-Salillas S. Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline. Arch Bronconeumol. 2009;45(2):100\u20132. \n https:\/\/doi.org\/10.1016\/j.arbres.2008.01.003\n \n .","journal-title":"Arch Bronconeumol."},{"issue":"12","key":"629_CR38","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/mds.20330","volume":"19","author":"KR Chaudhuri","year":"2004","unstructured":"Chaudhuri KR, Dhawan V, Basu S, Jackson G, Odin P. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord. 2004;19(12):1522\u20133. \n https:\/\/doi.org\/10.1002\/mds.20330\n \n .","journal-title":"Mov Disord."},{"issue":"8","key":"629_CR39","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1136\/hrt.2004.036236","volume":"90","author":"M Townsend","year":"2004","unstructured":"Townsend M, MacIver DH. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson\u2019s disease. Heart. 2004;90(8):e47. \n https:\/\/doi.org\/10.1136\/hrt.2004.036236\n \n .","journal-title":"Heart."},{"issue":"1","key":"629_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1445-5994.1991.tb03011.x-i1","volume":"21","author":"MA Hely","year":"1991","unstructured":"Hely MA, Morris JG, Lawrence S, Jeremy R, Genge S. Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy. Aust N Z J Med. 1991;21(1):82\u20134.","journal-title":"Aust N Z J Med."},{"issue":"8","key":"629_CR41","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/jnnp.57.8.903","volume":"57","author":"MA Hely","year":"1994","unstructured":"Hely MA, Morris JG, Reid WG, O\u2019Sullivan DJ, Williamson PM, Rail D, et al. The Sydney multicentre study of Parkinson\u2019s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry. 1994;57(8):903\u201310.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"629_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/pds.2267","volume":"21","author":"C Renoux","year":"2012","unstructured":"Renoux C, Dell\u2019Aniello S, Brophy JM, Suissa S. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf. 2012;21(1):34\u201341. \n https:\/\/doi.org\/10.1002\/pds.2267\n \n .","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"629_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med. 2007;356(1):39\u201346.","journal-title":"N Engl J Med."},{"issue":"1","key":"629_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29\u201338.","journal-title":"N Engl J Med."},{"issue":"6","key":"629_CR45","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","volume":"61","author":"G Camp Van","year":"2003","unstructured":"Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson\u2019s disease treated with high-dose pergolide. Neurology. 2003;61(6):859\u201361.","journal-title":"Neurology."},{"issue":"9416","key":"629_CR46","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/s0140-6736(04)15945-x","volume":"363","author":"G Camp Van","year":"2004","unstructured":"Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, et al. Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363(9416):1179\u201383. \n https:\/\/doi.org\/10.1016\/s0140-6736(04)15945-x\n \n .","journal-title":"Lancet."},{"issue":"1","key":"629_CR47","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11102-011-0339-7","volume":"15","author":"CL Boguszewski","year":"2012","unstructured":"Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012;15(1):44\u20139. \n https:\/\/doi.org\/10.1007\/s11102-011-0339-7\n \n .","journal-title":"Pituitary."},{"issue":"3","key":"629_CR48","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mds.22228","volume":"24","author":"LC Tan","year":"2009","unstructured":"Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC. Bromocriptine use and the risk of valvular heart disease. Mov Disord. 2009;24(3):344\u20139. \n https:\/\/doi.org\/10.1002\/mds.22228\n \n .","journal-title":"Mov Disord."},{"issue":"9","key":"629_CR49","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","volume":"6","author":"A Antonini","year":"2007","unstructured":"Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson\u2019s disease. Lancet Neurol. 2007;6(9):826\u20139.","journal-title":"Lancet Neurol."},{"issue":"2","key":"629_CR50","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1017\/S0317167100008593","volume":"35","author":"C Zadikoff","year":"2008","unstructured":"Zadikoff C, Duong-Hua M, Sykora K, Marras C, Lang A, Rochon P. Pergolide associated cardiac valvulopathy based on Ontario administrative data. Can J Neurol Sci. 2008;35(2):173\u20138.","journal-title":"Can J Neurol Sci."},{"issue":"12","key":"629_CR51","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-015-0293-4","volume":"29","author":"T Tran","year":"2015","unstructured":"Tran T, Brophy JM, Suissa S, Renoux C. Risks of cardiac valve regurgitation and heart failure associated with ergot- and non-ergot-derived dopamine agonist use in patients with Parkinson\u2019s disease: a systematic review of observational studies. CNS Drugs. 2015;29(12):985\u201398. \n https:\/\/doi.org\/10.1007\/s40263-015-0293-4\n \n .","journal-title":"CNS Drugs."},{"issue":"3","key":"629_CR52","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.phrs.2011.11.009","volume":"65","author":"MM Mokhles","year":"2012","unstructured":"Mokhles MM, Trifiro G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson\u2019s disease. Pharmacol Res. 2012;65(3):358\u201364. \n https:\/\/doi.org\/10.1016\/j.phrs.2011.11.009\n \n .","journal-title":"Pharmacol Res."},{"issue":"9","key":"629_CR53","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40266-013-0102-z","volume":"30","author":"PH Hsieh","year":"2013","unstructured":"Hsieh PH, Hsiao FY. Risk of heart failure associated with dopamine agonists: a nested case\u2013control study. Drugs Aging. 2013;30(9):739\u201345. \n https:\/\/doi.org\/10.1007\/s40266-013-0102-z\n \n .","journal-title":"Drugs Aging."},{"issue":"4","key":"629_CR54","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4065\/74.4.371","volume":"74","author":"LH Ling","year":"1999","unstructured":"Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson\u2019s disease. Mayo Clin Proc. 1999;74(4):371\u20135. \n https:\/\/doi.org\/10.4065\/74.4.371\n \n .","journal-title":"Mayo Clin Proc."},{"issue":"1","key":"629_CR55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/mds.22385","volume":"24","author":"F Andersohn","year":"2009","unstructured":"Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord. 2009;24(1):129\u201333. \n https:\/\/doi.org\/10.1002\/mds.22385\n \n .","journal-title":"Mov Disord."},{"issue":"10","key":"629_CR56","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1001\/archinte.1988.00380100089019","volume":"148","author":"NG McElvaney","year":"1988","unstructured":"McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson\u2019s disease. Arch Intern Med. 1988;148(10):2231\u20136.","journal-title":"Arch Intern Med."},{"issue":"3","key":"629_CR57","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/archneur.64.3.377","volume":"64","author":"RB Dewey 2nd","year":"2007","unstructured":"Dewey RB 2nd, Reimold SC, O\u2019Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol. 2007;64(3):377\u201380.","journal-title":"Arch Neurol."},{"issue":"47","key":"629_CR58","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1093\/eurheartj\/ehw229","volume":"37","author":"JL d\u2019Arcy","year":"2016","unstructured":"d\u2019Arcy JL, Coffey S, Loudon MA, Kennedy A, Pearson-Stuttard J, Birks J, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J. 2016;37(47):3515\u201322. \n https:\/\/doi.org\/10.1093\/eurheartj\/ehw229\n \n .","journal-title":"Eur Heart J."},{"issue":"20","key":"629_CR59","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484\u201391.","journal-title":"N Engl J Med."},{"issue":"7","key":"629_CR60","first-page":"1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial [erratum appears in Arch Neurol. 2005 Mar;62(3):430]. Arch Neurol. 2004;61(7):1044\u201353.","journal-title":"Arch Neurol."},{"issue":"15","key":"629_CR61","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931\u20138.","journal-title":"JAMA."},{"issue":"4","key":"629_CR62","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","volume":"51","author":"A Lieberman","year":"1998","unstructured":"Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson\u2019s disease. Ropinirole Study Group. Neurology. 1998;51(4):1057\u201362.","journal-title":"Neurology."},{"issue":"2","key":"629_CR63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00415-017-8671-0","volume":"265","author":"M Nomoto","year":"2018","unstructured":"Nomoto M, Iwaki H, Kondo H, Sakurai M. Efficacy and safety of rotigotine in elderly patients with Parkinson\u2019s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials. J Neurol. 2018;265(2):253\u201365. \n https:\/\/doi.org\/10.1007\/s00415-017-8671-0\n \n .","journal-title":"J Neurol."},{"issue":"1","key":"629_CR64","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1468-1331.2012.03712.x","volume":"20","author":"AH Schapira","year":"2013","unstructured":"Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, et al. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson\u2019s disease. Eur J Neurol. 2013;20(1):50\u20136. \n https:\/\/doi.org\/10.1111\/j.1468-1331.2012.03712.x\n \n .","journal-title":"Eur J Neurol."},{"issue":"16","key":"629_CR65","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.21741","volume":"22","author":"N Giladi","year":"2007","unstructured":"Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AHV, et al. Rotigotine transdermal patch in early Parkinson\u2019s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22(16):2398\u2013404.","journal-title":"Mov Disord."},{"issue":"10","key":"629_CR66","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/mds.25537","volume":"28","author":"Y Mizuno","year":"2013","unstructured":"Mizuno Y, Nomoto M, Kondo T, Hasegawa K, Murata M, Takeuchi M, et al. Transdermal rotigotine in early stage Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Mov Disord. 2013;28(10):1447\u201350. \n https:\/\/doi.org\/10.1002\/mds.25537\n \n .","journal-title":"Mov Disord."},{"issue":"12","key":"629_CR67","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.parkreldis.2014.10.005","volume":"20","author":"Y Mizuno","year":"2014","unstructured":"Mizuno Y, Nomoto M, Hasegawa K, Hattori N, Kondo T, Murata M, et al. Rotigotine vs ropinirole in advanced stage Parkinson\u2019s disease: a double-blind study. Parkinsonism Relat Disord. 2014;20(12):1388\u201393. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2014.10.005\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"629_CR68","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11318330-000000000-00000","volume":"27","author":"LD Wood","year":"2010","unstructured":"Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson\u2019s disease. Drugs Aging. 2010;27(4):295\u2013310. \n https:\/\/doi.org\/10.2165\/11318330-000000000-00000\n \n .","journal-title":"Drugs Aging."},{"issue":"5","key":"629_CR69","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40265-015-0377-y","volume":"75","author":"JP Elshoff","year":"2015","unstructured":"Elshoff JP, Cawello W, Andreas JO, Mathy FX, Braun M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson\u2019s disease and restless legs syndrome. Drugs. 2015;75(5):487\u2013501. \n https:\/\/doi.org\/10.1007\/s40265-015-0377-y\n \n .","journal-title":"Drugs."},{"issue":"12","key":"629_CR70","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1592\/phco.29.12.1452","volume":"29","author":"JJ Chen","year":"2009","unstructured":"Chen JJ, Swope DM, Dashtipour K, Lyons KE. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson\u2019s disease. Pharmacotherapy. 2009;29(12):1452\u201367. \n https:\/\/doi.org\/10.1592\/phco.29.12.1452\n \n .","journal-title":"Pharmacotherapy."},{"key":"629_CR71","unstructured":"Mirapex ER\u00ae Full prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. 2014. \n https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022421s003lbl.pdf\n \n . Accessed 8 July 2018."},{"key":"629_CR72","unstructured":"Requip\u00ae Full prescibing information. GlaxoSmithKline, Research Triangle Park. 2014. \n https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020658s024s026s027s030s032lbl.pdf\n \n . Accessed 8 July 2018."},{"issue":"4","key":"629_CR73","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","volume":"39","author":"CM Kaye","year":"2000","unstructured":"Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000;39(4):243\u201354. \n https:\/\/doi.org\/10.2165\/00003088-200039040-00001\n \n .","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"629_CR74","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/1531-8257(200007)15:4<664::AID-MDS1010>3.0.CO;2-D","volume":"15","author":"LM Shulman","year":"2000","unstructured":"Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson\u2019s disease. Mov Disord. 2000;15(4):664\u20138.","journal-title":"Mov Disord."},{"issue":"3","key":"629_CR75","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1517\/13543784.2014.869209","volume":"23","author":"F Blandini","year":"2014","unstructured":"Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson\u2019s disease. Expert Opin Investig Drugs. 2014;23(3):387\u2013410. \n https:\/\/doi.org\/10.1517\/13543784.2014.869209\n \n .","journal-title":"Expert Opin Investig Drugs."},{"issue":"Suppl 1","key":"629_CR76","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","volume":"55","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Early treatment of Parkinson\u2019s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. 1998;55(Suppl 1):23\u201330.","journal-title":"Drugs."},{"key":"629_CR77","doi-asserted-by":"publisher","first-page":"CD001518","DOI":"10.1002\/14651858.cd001518","volume":"1","author":"CE Clarke","year":"2001","unstructured":"Clarke CE, Deane KH. Cabergoline for levodopa-induced complications in Parkinson\u2019s disease. Cochrane Database Syst Rev. 2001;1:CD001518. \n https:\/\/doi.org\/10.1002\/14651858.cd001518\n \n .","journal-title":"Cochrane Database Syst Rev."},{"issue":"16","key":"629_CR78","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670\u201383. \n https:\/\/doi.org\/10.1001\/jama.2014.3654\n \n .","journal-title":"JAMA"},{"issue":"12","key":"629_CR79","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00702-003-0081-z","volume":"110","author":"H Reichmann","year":"2003","unstructured":"Reichmann H, Herting B, Miller A, Sommer U. Switching and combining dopamine agonists. J Neural Transm. 2003;110(12):1393\u2013400.","journal-title":"J Neural Transm."},{"issue":"3","key":"629_CR80","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448\u201358.","journal-title":"Mov Disord."},{"issue":"6902","key":"629_CR81","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/bmj.307.6902.469","volume":"307","author":"Parkinson\u2019s Disease Research Group in the United Kingdom","year":"1993","unstructured":"Parkinson\u2019s Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson\u2019s disease: three year interim report. BMJ. 1993;307(6902):469\u201372.","journal-title":"BMJ."},{"issue":"12","key":"629_CR82","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1001\/archneur.63.12.1756","volume":"63","author":"RA Hauser","year":"2006","unstructured":"Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63(12):1756\u201360. \n https:\/\/doi.org\/10.1001\/archneur.63.12.1756\n \n .","journal-title":"Arch Neurol."},{"issue":"2","key":"629_CR83","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/mds.870020201","volume":"2","author":"N Quinn","year":"1987","unstructured":"Quinn N, Critchley P, Marsden CD. Young onset Parkinson\u2019s disease. Mov Disord. 1987;2(2):73\u201391. \n https:\/\/doi.org\/10.1002\/mds.870020201\n \n .","journal-title":"Mov Disord."},{"issue":"3","key":"629_CR84","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/mds.20360","volume":"20","author":"N Kumar","year":"2005","unstructured":"Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson\u2019s disease onset. Mov Disord. 2005;20(3):342\u20134. \n https:\/\/doi.org\/10.1002\/mds.20360\n \n .","journal-title":"Mov Disord."},{"issue":"4","key":"629_CR85","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3988\/jcn.2010.6.4.159","volume":"6","author":"JE Ahlskog","year":"2010","unstructured":"Ahlskog JE. Seniors with Parkinson\u2019s disease: initial medical treatment. J Clin Neurol. 2010;6(4):159\u201366. \n https:\/\/doi.org\/10.3988\/jcn.2010.6.4.159\n \n .","journal-title":"J Clin Neurol."},{"issue":"2","key":"629_CR86","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1001\/archneur.63.2.205","volume":"63","author":"JA Gerpen Van","year":"2006","unstructured":"Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976\u20131990. Arch Neurol. 2006;63(2):205\u20139. \n https:\/\/doi.org\/10.1001\/archneur.63.2.205\n \n .","journal-title":"Arch Neurol."},{"issue":"9","key":"629_CR87","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1212\/01.wnl.0000210692.95595.1c","volume":"66","author":"CG Goetz","year":"2006","unstructured":"Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, Parkinson Study Group T, et al. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006;66(9):1427\u20139.","journal-title":"Neurology."},{"issue":"8","key":"629_CR88","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1248\u201366. \n https:\/\/doi.org\/10.1002\/mds.27372\n \n .","journal-title":"Mov Disord."},{"issue":"4","key":"629_CR89","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/WNF.0b013e31825f77b9","volume":"35","author":"Y Mizuno","year":"2012","unstructured":"Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, et al. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and l-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol. 2012;35(4):174\u201381. \n https:\/\/doi.org\/10.1097\/WNF.0b013e31825f77b9\n \n .","journal-title":"Clin Neuropharmacol."},{"issue":"11","key":"629_CR90","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.parkreldis.2013.07.009","volume":"19","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Wang J, Zhang X, Chen S, Wang Z, Zhang B, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson\u2019s disease: a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat Disord. 2013;19(11):1022\u20136. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2013.07.009\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"629_CR91","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00702-013-1008-y","volume":"120","author":"C Ossig","year":"2013","unstructured":"Ossig C, Reichmann H. Treatment of Parkinson\u2019s disease in the advanced stage. J Neural Transm. 2013;120(4):523\u20139. \n https:\/\/doi.org\/10.1007\/s00702-013-1008-y\n \n .","journal-title":"J Neural Transm."},{"key":"629_CR92","doi-asserted-by":"publisher","first-page":"CD007166","DOI":"10.1002\/14651858.cd007166.pub2","volume":"7","author":"R Stowe","year":"2010","unstructured":"Stowe R, Ives N, Clarke CE, Deane K, Wheatley K, Gray R, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010;7:CD007166. \n https:\/\/doi.org\/10.1002\/14651858.cd007166.pub2\n \n .","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"629_CR93","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/ageing\/32.3.244","volume":"32","author":"DG MacMahon","year":"2003","unstructured":"MacMahon DG. The initial drug treatment of older patients with Parkinson\u2019s disease\u2014consider an agonist, but don\u2019t demonise dopa. Age Ageing. 2003;32(3):244\u20135.","journal-title":"Age Ageing."},{"issue":"11","key":"629_CR94","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2165\/00002512-200320110-00006","volume":"20","author":"R Inzelberg","year":"2003","unstructured":"Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson\u2019s disease: an evidence-based comparison. Drugs Aging. 2003;20(11):847\u201355.","journal-title":"Drugs Aging."},{"issue":"2","key":"629_CR95","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/jnnp.51.2.244","volume":"51","author":"M Hietanen","year":"1988","unstructured":"Hietanen M, Teravainen H. The effect of age of disease onset on neuropsychological performance in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1988;51(2):244\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"12","key":"629_CR96","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1111\/j.1532-5415.2011.03689.x","volume":"59","author":"A Fasano","year":"2011","unstructured":"Fasano A, Guidubaldi A, De Nigris F, Bentivoglio AR. Safety and efficacy of rotigotine in individuals with Parkinson\u2019s disease aged 75 and older. J Am Geriatr Soc. 2011;59(12):2386\u20137. \n https:\/\/doi.org\/10.1111\/j.1532-5415.2011.03689.x\n \n .","journal-title":"J Am Geriatr Soc."},{"issue":"3","key":"629_CR97","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.parkreldis.2014.11.024","volume":"21","author":"D Woitalla","year":"2015","unstructured":"Woitalla D, Kassubek J, Timmermann L, Lauterbach T, Berkels R, Grieger F, et al. Reduction of gastrointestinal symptoms in Parkinson\u2019s disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. Parkinsonism Relat Disord. 2015;21(3):199\u2013204. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2014.11.024\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"629_CR98","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2125.2012.04193.x","volume":"73","author":"JM Ritter","year":"2012","unstructured":"Ritter JM. Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP). Br J Clin Pharmacol. 2012;73(3):331\u20134. \n https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04193.x\n \n .","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"629_CR99","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2012.373","volume":"108","author":"M Camilleri","year":"2013","unstructured":"Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L, American College of G. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18\u201337. \n https:\/\/doi.org\/10.1038\/ajg.2012.373\n \n .","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"629_CR100","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.parkreldis.2014.02.007","volume":"20","author":"T Umehara","year":"2014","unstructured":"Umehara T, Toyoda C, Oka H. Postprandial hypotension in de novo Parkinson\u2019s disease: a comparison with orthostatic hypotension. Parkinsonism Relat Disord. 2014;20(6):573\u20137. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2014.02.007\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"10","key":"629_CR101","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/archneur.60.10.1400","volume":"60","author":"U Bonuccelli","year":"2003","unstructured":"Bonuccelli U, Lucetti C, Del Dotto P, Ceravolo R, Gambaccini G, Bernardini S, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol. 2003;60(10):1400\u20134. \n https:\/\/doi.org\/10.1001\/archneur.60.10.1400\n \n .","journal-title":"Arch Neurol."},{"issue":"6 Pt 1","key":"629_CR102","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1161\/01.HYP.19.6.508","volume":"19","author":"GH Rutan","year":"1992","unstructured":"Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension. 1992;19(6 Pt 1):508\u201319.","journal-title":"Hypertension."},{"issue":"10","key":"629_CR103","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1001\/archneur.57.10.1461","volume":"57","author":"K Kujawa","year":"2000","unstructured":"Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson\u2019s disease. Arch Neurol. 2000;57(10):1461\u20133.","journal-title":"Arch Neurol."},{"issue":"12","key":"629_CR104","doi-asserted-by":"publisher","first-page":"M749","DOI":"10.1093\/gerona\/56.12.M749","volume":"56","author":"DJ Mehagnoul-Schipper","year":"2001","unstructured":"Mehagnoul-Schipper DJ, Boerman RH, Hoefnagels WH, Jansen RW. Effect of levodopa on orthostatic and postprandial hypotension in elderly Parkinsonian patients. J Gerontol A Biol Sci Med Sci. 2001;56(12):M749\u201355.","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"5","key":"629_CR105","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/archneur.58.5.835","volume":"58","author":"AE Lang","year":"2001","unstructured":"Lang AE. Acute orthostatic hypotension when starting dopamine agonist therapy in parkinson disease: the role of domperidone therapy. Arch Neurol. 2001;58(5):835.","journal-title":"Arch Neurol."},{"issue":"11","key":"629_CR106","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/mds.21428","volume":"22","author":"KL Schoffer","year":"2007","unstructured":"Schoffer KL, Henderson RD, O\u2019Maley K, O\u2019Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson\u2019s disease. Mov Disord. 2007;22(11):1543\u20139.","journal-title":"Mov Disord."},{"issue":"3","key":"629_CR107","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1517\/14740338.2014.888057","volume":"13","author":"S Perez-Lloret","year":"2014","unstructured":"Perez-Lloret S, Rey MV, Crispo J, Krewski D, Lapeyre-Mestre M, Montastruc JL, et al. Risk of heart failure following treatment with dopamine agonists in Parkinson\u2019s disease patients. Expert Opin Drug Saf. 2014;13(3):351\u201360. \n https:\/\/doi.org\/10.1517\/14740338.2014.888057\n \n .","journal-title":"Expert Opin Drug Saf."},{"key":"629_CR108","doi-asserted-by":"crossref","unstructured":"Investigators PSGCC. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66(5):563-70.","DOI":"10.1001\/archneurol.2009.32"},{"issue":"2","key":"629_CR109","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1212\/01.wnl.0000265593.34438.00","volume":"69","author":"KM Biglan","year":"2007","unstructured":"Biglan KM, Holloway RG Jr, McDermott MP, Richard IH, Parkinson Study Group C-PDI. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69(2):187\u201395.","journal-title":"Neurology."},{"issue":"3","key":"629_CR110","first-page":"169","volume":"21","author":"AE Schrag","year":"1998","unstructured":"Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson\u2019s disease. Clin Neuropharmacol. 1998;21(3):169\u201375.","journal-title":"Clin Neuropharmacol."},{"issue":"2","key":"629_CR111","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1517\/14740338.2016.1130128","volume":"15","author":"R Ceravolo","year":"2016","unstructured":"Ceravolo R, Rossi C, Del Prete E, Bonuccelli U. A review of adverse events linked to dopamine agonists in the treatment of Parkinson\u2019s disease. Expert Opin Drug Saf. 2016;15(2):181\u201398. \n https:\/\/doi.org\/10.1517\/14740338.2016.1130128\n \n .","journal-title":"Expert Opin Drug Saf."},{"issue":"1","key":"629_CR112","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/archneur.61.1.97","volume":"61","author":"A Razmy","year":"2004","unstructured":"Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol. 2004;61(1):97\u2013102. \n https:\/\/doi.org\/10.1001\/archneur.61.1.97\n \n .","journal-title":"Arch Neurol."},{"issue":"9","key":"629_CR113","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","volume":"52","author":"S Frucht","year":"1999","unstructured":"Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908\u201310.","journal-title":"Neurology."},{"issue":"1","key":"629_CR114","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90\u20139. \n https:\/\/doi.org\/10.1002\/mds.23441\n \n .","journal-title":"Mov Disord."},{"issue":"6","key":"629_CR115","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/WNF.0b013e3181a946d5","volume":"32","author":"PJ Garcia Ruiz","year":"2009","unstructured":"Garcia Ruiz PJ. Sleep attack associated to rotigotine. Clin Neuropharmacol. 2009;32(6):365. \n https:\/\/doi.org\/10.1097\/WNF.0b013e3181a946d5\n \n .","journal-title":"Clin Neuropharmacol."},{"issue":"3","key":"629_CR116","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1468-1331.2006.01262.x","volume":"13","author":"JJ Ferreira","year":"2006","unstructured":"Ferreira JJ, Desboeuf K, Galitzky M, Thalamas C, Brefel-Courbon C, Fabre N, et al. Sleep disruption, daytime somnolence and \u2018sleep attacks\u2019 in Parkinson\u2019s disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol. 2006;13(3):209\u201314. \n https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01262.x\n \n .","journal-title":"Eur J Neurol."},{"issue":"11","key":"629_CR117","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","volume":"18","author":"F Bracco","year":"2004","unstructured":"Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson\u2019s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18(11):733\u201346.","journal-title":"CNS Drugs."},{"issue":"2","key":"629_CR118","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","volume":"15","author":"JH Friedman","year":"2000","unstructured":"Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson\u2019s disease. Mov Disord. 2000;15(2):201\u201311.","journal-title":"Mov Disord."},{"issue":"3","key":"629_CR119","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/nejm199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162\u20137. \n https:\/\/doi.org\/10.1056\/nejm199307153290303\n \n .","journal-title":"N Engl J Med."},{"issue":"3","key":"629_CR120","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/01.pra.0000450319.21859.6d","volume":"20","author":"AA Shah","year":"2014","unstructured":"Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract. 2014;20(3):196\u2013206. \n https:\/\/doi.org\/10.1097\/01.pra.0000450319.21859.6d\n \n .","journal-title":"J Psychiatr Pract."},{"issue":"12","key":"629_CR121","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/jnnp-2017-315985","volume":"88","author":"N Warren","year":"2017","unstructured":"Warren N, O\u2019Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson\u2019s disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry. 2017;88(12):1060\u20134. \n https:\/\/doi.org\/10.1136\/jnnp-2017-315985\n \n .","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"629_CR122","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","volume":"41","author":"M Grall-Bronnec","year":"2018","unstructured":"Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, et al. Dopamine agonists and impulse control disorders: a complex association. Drug Saf. 2018;41(1):19\u201375. \n https:\/\/doi.org\/10.1007\/s40264-017-0590-6\n \n .","journal-title":"Drug Saf."},{"issue":"2","key":"629_CR123","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neurol.2011.07.010","volume":"168","author":"N Carriere","year":"2012","unstructured":"Carriere N, Kreisler A, Dujardin K, Destee A, Defebvre L. Impulse control disorders in Parkinson\u2019s disease: a cohort of 35 patients. Rev Neurol (Paris). 2012;168(2):143\u201351. \n https:\/\/doi.org\/10.1016\/j.neurol.2011.07.010\n \n .","journal-title":"Rev Neurol (Paris)."},{"issue":"3","key":"629_CR124","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mds.25291","volume":"28","author":"J Bastiaens","year":"2013","unstructured":"Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson\u2019s disease. Mov Disord. 2013;28(3):327\u201333. \n https:\/\/doi.org\/10.1002\/mds.25291\n \n .","journal-title":"Mov Disord."},{"issue":"6","key":"629_CR125","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/WNF.0b013e31826e6e6d","volume":"35","author":"S Perez-Lloret","year":"2012","unstructured":"Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):261\u20135. \n https:\/\/doi.org\/10.1097\/WNF.0b013e31826e6e6d\n \n .","journal-title":"Clin Neuropharmacol."},{"issue":"5","key":"629_CR126","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.parkreldis.2010.02.006","volume":"16","author":"M Sohtaoglu","year":"2010","unstructured":"Sohtaoglu M, Demiray DY, Kenangil G, Ozekmekci S, Erginoz E. Long term follow-up of Parkinson\u2019s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2010;16(5):334\u20137. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2010.02.006\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"629_CR127","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/wnf.0000000000000091","volume":"38","author":"A Todorova","year":"2015","unstructured":"Todorova A, Samuel M, Brown RG, Chaudhuri KR. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years\u2019 follow-up. Clin Neuropharmacol. 2015;38(4):132\u20134. \n https:\/\/doi.org\/10.1097\/wnf.0000000000000091\n \n .","journal-title":"Clin Neuropharmacol."},{"issue":"4","key":"629_CR128","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord. 2015;30(4):510\u20136. \n https:\/\/doi.org\/10.1002\/mds.26067\n \n .","journal-title":"Mov Disord."},{"issue":"1","key":"629_CR129","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/archneurol.2009.294","volume":"67","author":"CA Rabinak","year":"2010","unstructured":"Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58\u201363. \n https:\/\/doi.org\/10.1001\/archneurol.2009.294\n \n .","journal-title":"Arch Neurol."},{"issue":"9","key":"629_CR130","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.parkreldis.2012.05.012","volume":"18","author":"AL Cunnington","year":"2012","unstructured":"Cunnington AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(9):1051\u20132. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2012.05.012\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"5","key":"629_CR131","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H","volume":"15","author":"W Poewe","year":"2000","unstructured":"Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson\u2019s disease. Mov Disord. 2000;15(5):789\u201394.","journal-title":"Mov Disord."},{"issue":"2","key":"629_CR132","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1474-4422(13)70293-x","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa\u2013carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139. \n https:\/\/doi.org\/10.1016\/s1474-4422(13)70293-x\n \n .","journal-title":"Lancet Neurol."},{"issue":"8","key":"629_CR133","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.parkreldis.2015.05.014","volume":"21","author":"M Buongiorno","year":"2015","unstructured":"Buongiorno M, Antonelli F, Camara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, et al. Long-term response to continuous duodenal infusion of levodopa\/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord. 2015;21(8):871\u20136. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2015.05.014\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"Suppl 1","key":"629_CR134","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.parkreldis.2016.11.013","volume":"33","author":"N Titova","year":"2016","unstructured":"Titova N, Chaudhuri KR. Apomorphine therapy in Parkinson\u2019s and future directions. Parkinsonism Relat Disord. 2016;33(Suppl 1):S56\u201360. \n https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.013\n \n .","journal-title":"Parkinsonism Relat Disord."},{"issue":"5","key":"629_CR135","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s00415-017-8477-0","volume":"264","author":"A Sesar","year":"2017","unstructured":"Sesar A, Fernandez-Pajarin G, Ares B, Rivas MT, Castro A. Continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease: 10-year experience with 230 patients. J Neurol. 2017;264(5):946\u201354. \n https:\/\/doi.org\/10.1007\/s00415-017-8477-0\n \n .","journal-title":"J Neurol."},{"issue":"Pt 2","key":"629_CR136","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/brain\/124.2.331","volume":"124","author":"AJ Manson","year":"2001","unstructured":"Manson AJ, Hanagasi H, Turner K, Patsalos PN, Carey P, Ratnaraj N, et al. Intravenous apomorphine therapy in Parkinson\u2019s disease: clinical and pharmacokinetic observations. Brain. 2001;124(Pt 2):331\u201340.","journal-title":"Brain."},{"issue":"4","key":"629_CR137","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F","volume":"15","author":"J Kulisevsky","year":"2000","unstructured":"Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson\u2019s disease: a two-year follow-up study of previously untreated patients. Mov Disord. 2000;15(4):613\u201326.","journal-title":"Mov Disord."},{"issue":"1","key":"629_CR138","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/mdc3.12350","volume":"4","author":"S Isaacson","year":"2017","unstructured":"Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson\u2019s disease. Mov Disord Clin Pract. 2017;4(1):78\u201383. \n https:\/\/doi.org\/10.1002\/mdc3.12350\n \n .","journal-title":"Mov Disord Clin Pract."},{"issue":"2","key":"629_CR139","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40263-014-0221-z","volume":"29","author":"A Boyle","year":"2015","unstructured":"Boyle A, Ondo W. Role of apomorphine in the treatment of Parkinson\u2019s disease. CNS Drugs. 2015;29(2):83\u20139. \n https:\/\/doi.org\/10.1007\/s40263-014-0221-z\n \n .","journal-title":"CNS Drugs."},{"issue":"5","key":"629_CR140","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/imj.13378","volume":"47","author":"TE Kimber","year":"2017","unstructured":"Kimber TE, Fang J, Huddy LJ, Thompson PD. Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study. Intern Med J. 2017;47(5):570\u20133. \n https:\/\/doi.org\/10.1111\/imj.13378\n \n .","journal-title":"Intern Med J."},{"issue":"1","key":"629_CR141","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/mds.1276","volume":"17","author":"P Kanovsky","year":"2002","unstructured":"Kanovsky P, Kubova D, Bares M, Hortova H, Streitova H, Rektor I, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord. 2002;17(1):188\u201391. \n https:\/\/doi.org\/10.1002\/mds.1276\n \n .","journal-title":"Mov Disord."},{"issue":"9","key":"629_CR142","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/s1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749\u201359. \n https:\/\/doi.org\/10.1016\/s1474-4422(18)30239-4\n \n .","journal-title":"Lancet Neurol."},{"key":"629_CR143","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.archger.2004.04.039","volume":"9","author":"L Morgante","year":"2004","unstructured":"Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson\u2019s disease: a follow-up of two years. Arch Gerontol Geriatr Suppl. 2004;9:291\u20136. \n https:\/\/doi.org\/10.1016\/j.archger.2004.04.039\n \n .","journal-title":"Arch Gerontol Geriatr Suppl."},{"issue":"4","key":"629_CR144","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/mds.26485","volume":"31","author":"AE Lang","year":"2016","unstructured":"Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, et al. Integrated safety of levodopa\u2013carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016;31(4):538\u201346. \n https:\/\/doi.org\/10.1002\/mds.26485\n \n .","journal-title":"Mov Disord."},{"issue":"7","key":"629_CR145","doi-asserted-by":"publisher","first-page":"e00737","DOI":"10.1002\/brb3.737","volume":"7","author":"M Udd","year":"2017","unstructured":"Udd M, Lyytinen J, Eerola-Rautio J, Kentt\u00e4mies A, Lindstr\u00f6m O, Kyl\u00e4np\u00e4\u00e4 L, et al. Problems related to levodopa\u2013carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease. Brain Behav. 2017;7(7):e00737. \n https:\/\/doi.org\/10.1002\/brb3.737\n \n .","journal-title":"Brain Behav."},{"issue":"4","key":"629_CR146","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/mds.26528","volume":"31","author":"A Antonini","year":"2016","unstructured":"Antonini A, Fung VSC, Boyd JT, Slevin JT, Hall C, Chatamra K, et al. Effect of levodopa\u2013carbidopa intestinal gel on dyskinesia in advanced Parkinson\u2019s disease patients. Mov Disord. 2016;31(4):530\u20137. \n https:\/\/doi.org\/10.1002\/mds.26528\n \n .","journal-title":"Mov Disord."},{"issue":"10","key":"629_CR147","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1001\/jamaneurol.2014.1272","volume":"71","author":"MR DeLong","year":"2014","unstructured":"DeLong MR, Huang KT, Gallis J, Lokhnygina Y, Parente B, Hickey P, et al. Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease. JAMA Neurol. 2014;71(10):1290\u20135. \n https:\/\/doi.org\/10.1001\/jamaneurol.2014.1272\n \n .","journal-title":"JAMA Neurol."},{"issue":"12","key":"629_CR148","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/mds.25610","volume":"28","author":"AI Rughani","year":"2013","unstructured":"Rughani AI, Hodaie M, Lozano AM. Acute complications of movement disorders surgery: effects of age and comorbidities. Mov Disord. 2013;28(12):1661\u20137. \n https:\/\/doi.org\/10.1002\/mds.25610\n \n .","journal-title":"Mov Disord."},{"issue":"5","key":"629_CR149","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/ana.23890","volume":"73","author":"R-M Souza de","year":"2013","unstructured":"de Souza R-M, Moro E, Lang AE, Schapira AH. Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol. 2013;73(5):565\u201375. \n https:\/\/doi.org\/10.1002\/ana.23890\n \n .","journal-title":"Ann Neurol."},{"issue":"3","key":"629_CR150","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jamaneurol.2014.4216","volume":"72","author":"CC Aquino","year":"2015","unstructured":"Aquino CC, Lozano AM, Lang AE. Deep brain stimulation for Parkinson disease in elderly individuals. JAMA Neurol. 2015;72(3):367. \n https:\/\/doi.org\/10.1001\/jamaneurol.2014.4216\n \n .","journal-title":"JAMA Neurol."},{"issue":"10","key":"629_CR151","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1212\/01.WNL.0000144198.26309.D8","volume":"63","author":"H Russmann","year":"2004","unstructured":"Russmann H, Ghika J, Villemure JG, Robert B, Bogousslavsky J, Burkhard PR, et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology. 2004;63(10):1952\u20134.","journal-title":"Neurology."},{"issue":"17","key":"629_CR152","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1212\/01.wnl.0000260059.77107.c2","volume":"68","author":"PP Derost","year":"2007","unstructured":"Derost PP, Ouchchane L, Morand D, Ulla M, Llorca PM, Barget M, et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology. 2007;68(17):1345\u201355. \n https:\/\/doi.org\/10.1212\/01.wnl.0000260059.77107.c2\n \n .","journal-title":"Neurology."},{"issue":"8","key":"629_CR153","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","volume":"28","author":"T Kvernmo","year":"2006","unstructured":"Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28(8):1065\u201378. \n https:\/\/doi.org\/10.1016\/j.clinthera.2006.08.004\n \n .","journal-title":"Clin Ther."},{"issue":"7","key":"629_CR154","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1517\/17425255.2013.789018","volume":"9","author":"JA Agundez","year":"2013","unstructured":"Agundez JA, Garcia-Martin E, Alonso-Navarro H, Jimenez-Jimenez FJ. Anti-Parkinson\u2019s disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol. 2013;9(7):859\u201374. \n https:\/\/doi.org\/10.1517\/17425255.2013.789018\n \n .","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"3","key":"629_CR155","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/sj.bjp.0705962","volume":"143","author":"ZA Abassi","year":"2004","unstructured":"Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol. 2004;143(3):371\u20138.","journal-title":"Br J Pharmacol."},{"issue":"12","key":"629_CR156","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","volume":"59","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937\u201343.","journal-title":"Arch Neurol."},{"issue":"3","key":"629_CR157","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14740338.2018.1433659","volume":"17","author":"A Castro Caldas","year":"2018","unstructured":"Castro Caldas A, Teodoro T, Ferreira JJ. The launch of opicapone for Parkinson\u2019s disease: negatives versus positives. Expert Opin Drug Saf. 2018;17(3):331\u20137. \n https:\/\/doi.org\/10.1080\/14740338.2018.1433659\n \n .","journal-title":"Expert Opin Drug Saf."},{"issue":"1","key":"629_CR158","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41531-018-0070-4","volume":"4","author":"B Cruse","year":"2018","unstructured":"Cruse B, Morales-Brice\u00f1o H, Chang FCF, Mahant N, Ha AD, Kim SD, et al. 24-hour levodopa\u2013carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson\u2019s disease. NPJ Parkinson\u2019s Dis. 2018;4(1):34. \n https:\/\/doi.org\/10.1038\/s41531-018-0070-4\n \n .","journal-title":"NPJ Parkinson\u2019s Dis."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-018-0629-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0629-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0629-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T19:13:02Z","timestamp":1578510782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-018-0629-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":158,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0629-0","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]},"assertion":[{"value":"9 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No specific funding was received for this work by Mark Dominic Latt, Simon Lewis, Olfat Zekry or Victor S. C. Fung.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mark Dominic Latt and Olfat Zekry report no conflicts of interest or additional disclosures. Simon Lewis reports honoraria from Stada and Teva. Victor S. C. Fung is a member of advisory boards for Abbvie, Allergan, Ipsen, Merz, Stada, Teva and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}